Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis – Clinical Implications in the Treatment of Patients with Type 2 Diabetes

The use of sodium-glucose cotransporter 2 inhibitors is associated with an increased risk of diabetic ketoacidosis. This risk has been reported in particular in off-label use of these agents in type 1 diabetes, but reports of risks in type 2 diabetes patients also exist. In type 2 diabetes ketoacido...

Descripción completa

Detalles Bibliográficos
Autores principales: Stinkens, Kirsten, Mathieu, Chantal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2016
Materias:
Diabetes Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813456/
https://www.ncbi.nlm.nih.gov/pubmed/29632585
http://dx.doi.org/10.17925/EE.2016.12.01.33
_version_ 1783300200565047296
author Stinkens, Kirsten
Mathieu, Chantal
author_facet Stinkens, Kirsten
Mathieu, Chantal
author_sort Stinkens, Kirsten
collection PubMed
description The use of sodium-glucose cotransporter 2 inhibitors is associated with an increased risk of diabetic ketoacidosis. This risk has been reported in particular in off-label use of these agents in type 1 diabetes, but reports of risks in type 2 diabetes patients also exist. In type 2 diabetes ketoacidosis is rare and is present particularly in patients who have undergone prolonged starvation, serious infection, alcohol abuse or surgery. The pleiotropic advantages of sodium-glucose cotransporter 2 inhibitors do not outweigh the risk for a diabetic ketoacidosis, but caution is warranted.
format Online
Article
Text
id pubmed-5813456
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Touch Medical Media
record_format MEDLINE/PubMed
spelling pubmed-58134562018-04-09 Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis – Clinical Implications in the Treatment of Patients with Type 2 Diabetes Stinkens, Kirsten Mathieu, Chantal Eur Endocrinol Diabetes Editorial The use of sodium-glucose cotransporter 2 inhibitors is associated with an increased risk of diabetic ketoacidosis. This risk has been reported in particular in off-label use of these agents in type 1 diabetes, but reports of risks in type 2 diabetes patients also exist. In type 2 diabetes ketoacidosis is rare and is present particularly in patients who have undergone prolonged starvation, serious infection, alcohol abuse or surgery. The pleiotropic advantages of sodium-glucose cotransporter 2 inhibitors do not outweigh the risk for a diabetic ketoacidosis, but caution is warranted. Touch Medical Media 2016-03 2016-03-15 /pmc/articles/PMC5813456/ /pubmed/29632585 http://dx.doi.org/10.17925/EE.2016.12.01.33 Text en © The Author(s) 2016 http://creativecommons.org/licenses/by/2.5/ This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.
spellingShingle Diabetes Editorial
Stinkens, Kirsten
Mathieu, Chantal
Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis – Clinical Implications in the Treatment of Patients with Type 2 Diabetes
title Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis – Clinical Implications in the Treatment of Patients with Type 2 Diabetes
title_full Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis – Clinical Implications in the Treatment of Patients with Type 2 Diabetes
title_fullStr Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis – Clinical Implications in the Treatment of Patients with Type 2 Diabetes
title_full_unstemmed Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis – Clinical Implications in the Treatment of Patients with Type 2 Diabetes
title_short Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis – Clinical Implications in the Treatment of Patients with Type 2 Diabetes
title_sort sodium-glucose cotransporter 2 inhibitors and ketoacidosis – clinical implications in the treatment of patients with type 2 diabetes
topic Diabetes Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813456/
https://www.ncbi.nlm.nih.gov/pubmed/29632585
http://dx.doi.org/10.17925/EE.2016.12.01.33
work_keys_str_mv AT stinkenskirsten sodiumglucosecotransporter2inhibitorsandketoacidosisclinicalimplicationsinthetreatmentofpatientswithtype2diabetes
AT mathieuchantal sodiumglucosecotransporter2inhibitorsandketoacidosisclinicalimplicationsinthetreatmentofpatientswithtype2diabetes

Ejemplares similares